21 research outputs found

    Introduction to special issue on Webster

    Get PDF
    John Webster’s Theater of (Dis)obedience and Damnation: A collection of essays exploring the forms and functions of violence, evil, and social realities in Webster's drama

    Growth by destination: the role of trade in Africa's recent growth episode

    Get PDF
    Over the period 1990–2009, Africa has experienced a distinct and favourable reversal in its growth fortunes in stark contrast to its performance in the preceding decades, leading to a variety of hypotheses seeking to explain the phenomenon. This paper presents both cross-country and panel-data evidence on the causal factors driving the recent turnaround in Africa's growth and takes the unique approach of disaggregating the separate growth impacts of Africa's bilateral trade with: China, Europe and America. The empirical analysis presented in this paper suggests that the primary and most robust causal factors driving Africa's recent growth turnaround are private sector- and foreign direct investment. Although empirical evidence of the role of bilateral trade openness in Africa's recent growth emerges within a fixed effect estimation setting, these results are not as robust when endogeneity and other issues are fully accounted for. Among the three major bilateral partners, Africa's bilateral trade with China has been a relatively important factor spurring growth on the continent and especially so in resource-rich, oil producing and non-landlocked countries. The econometric results are not as supportive of growth-inducing effects of foreign aid. These findings emerge after applying a variety of panel data specifications to the data, including the recent fixed Effects Filtered (FEF) estimator introduced by Pesaran and Zhou (2014) and the dynamic panel Generalized Method of Moments (GMM) estimator, which allows for endogeneity between trade and growth

    ANTIPROLIFERATIVE COMPOUNDS AND THERAPEUTIC USES THEREOF

    No full text
    nhibitors of the oncogenic tyrosine kinase ALK and of the Bcr-Abl mutant T3 15I Bcr-Abl, pharmaceutical com positions comprising the same and the use thereof for the treatment of hyper-proliferative diseases
    corecore